ESPR Quote, Financials, Valuation and Earnings

Heron Therapeutics has a net margin of -30.85% compared to Esperion Therapeutics's net margin of 6.77%. Esperion Therapeutics's return on equity of -- beat Heron Therapeutics's return on equity of --.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 548.04%. On the other hand Heron Therapeutics has an analysts' consensus of $6.33 which suggests that it could grow by 191.86%. Given that Esperion Therapeutics has higher upside potential than Heron Therapeutics, analysts believe Esperion Therapeutics is more attractive than Heron Therapeutics.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.328, suggesting its more volatile than the S&P 500 by 32.785%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Heron Therapeutics quarterly revenues of $38.9M. Esperion Therapeutics's net income of -$21.3M is lower than Heron Therapeutics's net income of $2.6M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.52x versus 2.23x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -598.74%. Esperion Therapeutics's return on equity of -- beat Ocular Therapeutix's return on equity of -56.05%.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 548.04%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 134.9%. Given that Esperion Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Esperion Therapeutics is more attractive than Ocular Therapeutix.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. Esperion Therapeutics's net income of -$21.3M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.52x versus 20.93x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -30.85% compared to Esperion Therapeutics's net margin of --. Esperion Therapeutics's return on equity of -- beat Plus Therapeutics's return on equity of --.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 548.04%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 1486.02%. Given that Plus Therapeutics has higher upside potential than Esperion Therapeutics, analysts believe Plus Therapeutics is more attractive than Esperion Therapeutics.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Plus Therapeutics quarterly revenues of --. Esperion Therapeutics's net income of -$21.3M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.52x versus 0.76x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -30.85% compared to Esperion Therapeutics's net margin of -8.51%. Esperion Therapeutics's return on equity of -- beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 548.04%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.25 which suggests that it could grow by 21.12%. Given that Esperion Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Esperion Therapeutics is more attractive than Xeris Biopharma Holdings.

Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.36%.

Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Esperion Therapeutics quarterly revenues are $69.1M, which are larger than Xeris Biopharma Holdings quarterly revenues of $60.1M. Esperion Therapeutics's net income of -$21.3M is lower than Xeris Biopharma Holdings's net income of -$5.1M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.52x versus 3.73x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.